Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chikusetsusaponin Ib is a natural triterpenoid saponin compound isolated from the leaves and rhizomes of *Panax japonicus* (Japanese ginseng). It functions as a potent inhibitor of acetylcholinesterase (AChE), the primary enzyme responsible for the degradation of the neurotransmitter acetylcholine in the synaptic cleft. Preclinical studies, including evaluations in PC12 cell models, have demonstrated that Chikusetsusaponin Ib possesses anti-Alzheimer's disease activity and neuroprotective potential. Currently, the compound is primarily utilized as a chemical reagent for laboratory research and is not approved for clinical use. It has also been explored as a potential functional food or nutraceutical ingredient due to its bioactive properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chikusetsusaponin ib.